Blood test to predict tumor recurrence of advanced skin cancer called highly accurate
ST. PAUL, Minn., April 15 (UPI) -- New York University researchers say a simple, gene-based blood test has shown to be highly accurate in predicting whether some stage III melanoma patients are likely to suffer recurrences of cancerous tumors.
The new test looks for a specific type of DNA shed by tumors of stage III melanoma patients who, if found, indicates a strong likelihood their cancer will return in the aftermath of lymph node surgery, according to the authors of a study published Tuesday in The Lancet Oncology.
Stage III melanoma is an advanced form of skin cancer in which the malignancy has spread beyond the original site to nearby lymph nodes or surrounding tissue, requiring aggressive treatment such as surgery, immunotherapy or targeted therapy to restrict its progression.
Using the new test, an analysis of hundreds of blood plasma samples taken from stage III melanoma patients with mutated BRAF genes -- who make up about half of all skin cancer sufferers -- determined that approximately 80% of those who had evidence of circulating tumor DNA, or ctDNA, in their samples eventually went on to develop recurrences of their cancers.
The research was funded by the Swiss pharmaceutical giant Novartis, maker of the melanoma-inhibiting drugs Tafinlar and Mekinist.
The high level of prediction accuracy means oncologists and dermatologists may soon have a valuable new tool to quickly and easily tell which patients are most likely to respond well to follow-on "adjuvant" therapy after surgery, according to Dr. David Polsky, the Alfred W. Kopf Professor of Dermatologic Oncology in the Ronald O. Perelman Department of Dermatology at NYU, as well as an advisory board member for Novartis.
"We think [patients with resected stage III melanoma] would most likely benefit from ctDNA measurements shortly after their surgery -- [for example} within 12 weeks or less as was done in this study -- and periodically thereafter," Polsky told UPI in emailed comments.
Those patients, he said, would for the first time have a "clear, direct measure of the disease itself" -- a significant improvement over the current method of tissue-based analyses of tumor cells that can only suggest the likelihood of recurrence.
Potential benefits
Where the new test could have particularly strong benefits is among melanoma patients who have undergone successful lymph node resections and are currently cancer-free, but who choose to forego follow-up drug therapy due to financial burdens or other reasons. An accurate test for ctDNA could identify which of them are at higher risk and most in need of adjuvant therapy, Polsky said.
"Also, we did have samples from some patients who completed a year of treatment and then stopped their treatment according to the protocol rules," he added. "In some of those patients we detected ctDNA beginning mostly three months after stopping treatment.
"So, another group of patients who might benefit from the test are those patients with resected stage III melanoma who stop their adjuvant therapy and would like to have a blood test to help identify melanoma recurrence should it happen."
Although the test did not detect ctDNA in every patient who eventually recurred, when the test was positive, nearly everybody in that group developed a recurrence detectable on a radiographic scan, Polsky said, adding, "We're hoping that with additional study this test can become part of the routine work-up for patients with melanoma that has escaped the skin and spread to other parts of the body."
Doctors who see a positive ctDNA test result in patients carrying a mutation of the BRAF gene could then take proactive steps, such as ordering a computed tomography, or CT, scan ahead of schedule or requesting a more sensitive PET-CT scan, the authors suggest.
Latest evidence
The study "adds to the increasing evidence that circulating tumor DNA has a useful role in patients where the cancer has been surgically resected and patients are at high risk of recurrence," said Dr. Alastair Greystoke, an oncologist at the Northern Center for Cancer Care in Newcastle-upon-Tyne, England, and an authority on genetic cancer biomarkers. He was not involved in the NYU study.
"[The authors] showed with a robust and relatively cheap blood test that you could predict patients who were likely to relapse following surgery for melanoma that had spread to the lymph nodes, where we hope patients are cured but there is a high chance it will come back," Greystoke told UPI.
"At the moment, these patients are offered extra treatment with targeted drugs or immunotherapy, which reduce the chance of recurrence, but these drugs are expensive can be associated with significant and life changing side-effects and are not needed by all."
Overall, the noted oncologist added, "this study adds to the utility of ctDNA, moving it strongly into the detection and measurement of minimal residual disease to inform decision-making in patients who have had surgery for BRAF-mutated melanoma. It is likely we will see increasing use in this and other tumor types."
Meanwhile, the leader of the world's largest private nonprofit funder of melanoma research told UPI the results of the NYU study are "exciting" and part of a "promising" front in the fight against the disease.
"CtDNA monitoring appears promising to help guide treatment escalation, switching, or de-escalation," said Dr. Marc Hurlbert, CEO of the Melanoma Research Alliance.
Evidence is mounting that keeping an eye on levels of tumor-related genetic material can help in many areas of melanoma treatment, such as identifying patients at high risk of recurrence, monitoring response to treatments, helping to guide treatment selection, signaling "when a switch from an approved agent to a clinical trial might be necessary, and lastly to augment imaging tests for monitoring for disease recurrence," he said.
Hurlbert noted his alliance has funded previous research on analyzing bloodstream biomarkers to detect cancer risk, including an study published this month in which scientists applied low-cost, whole-genome sequencing techniques to ctDNA to identify risks of mutations.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Boston Globe
an hour ago
- Boston Globe
What makes a food ultraprocessed? The FDA is about to weigh in.
Get Starting Point A guide through the most important stories of the morning, delivered Monday through Friday. Enter Email Sign Up Dr. Marty Makary, the commissioner of the FDA, said he expected the definition would encourage companies to label foods as 'non-ultraprocessed' to entice customers, similar to how food manufacturers market their products as being free from added sugars. Advertisement 'We do not see ultraprocessed foods as foods to be banned,' he said. 'We see them as foods to be defined so that markets can compete based on health.' The idea that consumers may go out of their way to avoid these items reflects growing concerns about the potential harms of ultraprocessed foods, which include many breakfast cereals, instant noodles, protein bars, meal-replacement shakes, flavored yogurts, hot dogs and more. Scientists have increasingly linked ultraprocessed foods to poor health outcomes, such as Type 2 diabetes, some types of cancers, and heart and gastrointestinal issues. Advertisement Kyle Diamantas, the deputy commissioner of the FDA's food division, said that there were some 'obvious areas' the agency would consider when crafting its definition, including synthetic dyes, emulsifiers and preservatives. 'We don't have in our home kitchens these new novel ingredients that help a Twinkie stay on the shelf for six years or whatever it might be,' Diamantas said. He also suggested that a standard definition of ultraprocessed foods could be used for regulating the meals served to members of the military and at prisons and Veterans Affairs hospitals. The government will almost certainly face pushback from some corners of the food industry, which has relied on preservatives and artificial ingredients to produce cheap, convenient foods at a large scale. Related : Any definition the government comes up with would be 'hotly contested' by the food industry, said Marion Nestle, an emerita professor of nutrition, food studies and public health at New York University. By defining ultraprocessed foods, the government will also weigh in on issues that have divided nutrition experts and confused consumers: Do plant-based meats and milks belong in the same category as sodas and candy bars? And are all ultraprocessed foods inherently unhealthy? Some, like various yogurts and whole-grain breads and cereals, contain valuable nutrients and have been associated with positive health outcomes. The broad term can 'demonize' foods that aren't necessarily harming consumers, said Maya Vadiveloo, an associate professor of nutrition at the University of Rhode Island. Advertisement The federal push follows recent efforts in a handful of states to restrict ultraprocessed foods sold and served in schools. In Arizona, lawmakers defined ultraprocessed foods only as those with certain food additives, like artificial dyes. But additives may only be one part of what makes certain ultraprocessed foods unhealthy, said Brenda Davy, a professor of nutrition at Virginia Tech — and if the federal definition follows Arizona's example, it would likely miss a great number of ultraprocessed foods, she said, like a sugar-loaded cereal that does not use certain food colorings. 'If their focus is too narrow, it may be limited in how much that might improve health,' she said. Still, a federal definition would be a 'big step forward,' Nestle said. It could pave the way for new types of warning labels, or for the government to regulate whether food makers could continue marketing ultraprocessed foods to children, she said. 'All of those are up for grabs if there's a definition,' she said. She added: 'It matters a lot.' This article originally appeared in .


UPI
3 hours ago
- UPI
Watch: Gaal takes on the Mule in 'Foundation' Season 3 trailer
1 of 3 | Apple TV+ is previewing Season 3 of "Foundation." Photo courtesy of Apple TV+ June 11 (UPI) -- Voyagers actress Lou Llobell and Game of Thrones actor Pilou Asbaek prepare to face off in a new trailer for Foundation Season 3, released Wednesday. Llobell portrays Gaal in the sci-fi series inspired by the Isaac Asimov novels. Asbaek joins the cast as the Mule, a warlord who poses "a threat to the entire galaxy," according to an official synopsis. "You think I'm a monster?" he asks in the preview. "I have talents, you see. I can worm my way into people's minds. Convert enemies into allies. Hate into love." Hari (Jared Harris) tells Gaal that her battle is with the Mule. "It's my job to ensure you're prepared." he says. "The Mule's abilities are far beyond anything I can do," she responds. Season 3 takes place more than a century after Season 2, according to the synopsis. The upcoming chapter also stars Cherry Jones, Brandon P. Bell, Synnove Karlsen, Cody Fern, Tomas Lemarquis, Alexander Siddig, Troy Kotsur, Laura Birn, Cassian Bilton, Terrence Mann and Rowena King. Season 3 premieres July 11 on Apple TV+.
Yahoo
8 hours ago
- Yahoo
"STRONGER TOGETHER": SWITZERLAND CHAMPIONS INTERNATIONAL PARTNERSHIPS AS KEY TO ACCELERATED INNOVATION", ONCE AGAIN SWITZERLAND IS SHOWCASING ITS BIOTECH EXCELLENCE AT BIO INTERNATIONAL IN BOSTON 16-19 JUNE, 2025
Swiss biotech excellence returns to BIO 2025 in Boston, where Switzerland Global Enterprise presents 45 cutting-edge Swiss companies at the SWISS BIOTECH pavilion, booth #2345, showcasing the country's healthcare innovation leadership. ZURICH, June 11, 2025 /PRNewswire/ -- The represented biotech companies primarily focus on therapeutics development across oncology, respiratory diseases, rare diseases, and CNS disorders, alongside advanced drug discovery technologies including 3D microtissues, transcriptomics, and novel delivery systems. Switzerland's biotech sector thrives on international collaboration, with 80% of Swiss biotech patents resulting from partnerships rather than competition. The country leverages its diverse talent pool and takes leadership roles in global initiatives like the 47-country Eureka network (chaired by Innosuisse) and the Access Consortium for joint regulatory approvals. This collaborative approach spans from research to market access, positioning Switzerland as a valuable global partner in solving health care challenges. In short: "Switzerland's collaborative model offers a compelling counterproposal to 'me first' approaches, fostering international knowledge exchange to become stronger, faster and smarter together", says Michael Altorfer CEO, Swiss Biotech Association. Switzerland Global Enterprise with its partner Swissnex in Boston and New York will be hosting a Swiss "Wine and Cheese" reception on Tuesday June 17th from 5pm to 6:30pm at the Swiss Pavilion, booth #2345. Alithea Genomics Global leader in scalable transcriptomics solutions for screening applications. Altamira Therapeutics AG Developing and supplying peptide-based nanoparticle technologies for efficient RNA delivery to extrahepatic tissues (xPhore™ platform). BioAlps Association Acts as a life sciences cluster promoting networking and collaboration in the BioAlps community. Bioengineering AG Provides solutions in bioprocess engineering, ranging from development to production scale. Biopôle SA Operates a life sciences campus that supports innovation and development in the healthcare and biotech sectors. Bioscibex Providing cutting-edge bioreactor technologies that simplify and automate cell-based therapies. BioVersys AG Promotes Switzerland as a prime location for business and investment. CDR-Life AG Developing highly specific antibody therapeutics to target intracellular proteins presented on the major histocompatibility complex (MHC). EM Microelectronic Semiconductor manufacturer specialized in the design and production of ultra-low power, low voltage integrated circuits (IC) for battery-operated and field-powered applications. Enantios AG Utilizes cutting edge technology to analyze chiral molecules and biologics. EPIC Suisse Property Management GmbH Offers comprehensive property management services across Switzerland. Ibex Therapeutics SA Developing a patented oral topical therapy to cure and prevent oral mucositis and oral candidiasis. InSphero AG Develops and produces 3D microtissues for drug discovery and toxicity testing. KPMG Offers audit, tax, and advisory services to help organizations. Limula SA They provide a unique platform technology that enable manufacturing of clinical-grade cell products at scale, through automation and standardization. Molecular Partners AG Develops a new class of custom-built protein therapeutics known as DARPin® molecules. Ninsun Biotech Revolutionizing the marking of cancer stem cells by offering a specific biomarker for several cancers, including lung, breast and colon Novavax Proven vaccine technology, focused on developing R&D assets and establishing partnerships to leverage the value of the technology to help protect health. NXI Therapeutics AG Developing selective immunomodulators, which regulate T cell immune responses that play a key role in graft rejection and autoimmunity, while leaving the protective responses against infections and vaccination intact. ObelysQ SA Quality assurance consulting firm offering tailored solutions to the pharma industry aiming at enhancing compliance and improving processes in the execution of clinical trials. OM Pharma Engages in the research, development, and marketing of medicines in respiratory and vascular diseases. PDC Therapeutics Focuses on developing precision drugs for the treatment of severe and rare diseases. Perseo Pharma AG Breaking new ground in the treatment of metabolic diseases Polaroid Therapeutics Proprietary technology represents a significant advancement in antimicrobial therapies, setting a new standard in the industry. Superlab Suisse AG Provides high-tech laboratory services and research facilities for life sciences companies. Tigermed Swiss SA Offers clinical trial management and pharmaceutical consulting services. Venture Valuation Inc. Specializes in the assessment and valuation of growth companies in the life sciences and technology sectors. Cellvie Dedicated to advancing mitochondrial transplantation therapy to treat acute and chronic degenerative diseases. FluoSphera Provides high-throughput screening services using innovative fluorescence-based technologies. Nagi Bioscience Develops the first Organism-on-Chip technology for automated and ethical testing of drugs and chemicals. REM Analytics SA Specializes in microbiome analytics and solutions for healthcare and agricultural applications. Synendos Therapeutics AG Focuses on the development of breakthrough therapies for the treatment of central nervous system disorders. Vandria Offers digital solutions to enhance the efficiency and effectiveness of healthcare and medical management. Alpha Onco Engages in the development of innovative oncology treatments. BioArk Provides infrastructure and support for startups and established companies in the life sciences sector. Ceidos SA Specializes in virtual reality solutions, primarily for therapeutic and rehabilitation applications. Excellgene Produces biopharmaceuticals using advanced cell line engineering and protein production technologies. Immunskills Offers workshops and training in immunotherapy and biological production. Novochizol SA Develops chitosan-based formulations to enhance the delivery of biopharmaceuticals. Orio Therapeutics Specializes in developing therapies for respiratory diseases. SETI / Canton VS Supports economic development in Valais, particularly in the sectors of technology, education, and innovation. Stämm Biotech Works on bioprocesses that utilize human stem cells for regenerative medicine. Swiss Biotech Center Provides laboratory services, R&D, and consulting to foster innovation in biotechnology. ten23 health Valais Ltd. Offers services in drug development and manufacturing, with a focus on sustainable practices. Ymmunobio AG Ymmunobio AG is a preclinical stage biotechnology company developing a novel class of immune oncology therapeutic antibodies. The SWISS BIOTECH companies will be available for media and partner interviews the entire week. Media Contacts Partnerships & Business Development Lisette Müry Karine J. Wittmer E: E. Trade Fairs Foreign Direct Investment Export Promotion & Global Network Trade Commissioner Bettina Thomas Sean Powers E: Bthomas@ E: About Switzerland Global EnterpriseSwitzerland Global Enterprise (S-GE) is the official Swiss organization for export and investment promotion with around 200 employees at locations throughout Switzerland and overseas. S-GE supports Swiss SMEs in their international business and helps innovative foreign companies to settle in Switzerland. In doing so, we rely on a unique network of national and international partners. This allows us to create added value for our customers and prosperity for Switzerland. As a non-profit organization, we provide a public service for our clients on behalf of the Swiss Confederation (State Secretariat for Economic Affairs SECO) and the cantons. We operate our 27 offices, the so-called Swiss Business Hubs, and Trade Points, in 31 countries jointly with the Federal Department of Foreign Affairs (FDFA). Thanks to our global network of partners, we also support our customers in many other countries. View original content to download multimedia: SOURCE Swiss Business Hub USA Sign in to access your portfolio